Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
Completed
Yungjin Pharm. Co., Ltd.
Phase 1
The purpose of this First In Human study is to investigate the safety and tolerability of
KL1333 after a single oral dose and to investigate the pharmacokinetic characteristics of
KL1333 after a single oral dose.
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
Completed
Abliva AB
Phase 1
This will be a double blind, randomised, placebo controlled, single and multiple oral dose
study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy
volunteers only and will be completed before Part C including patients with primary
mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will
be 25 mg. The dose level in the additional cohorts will be decided following review of data
of the previous cohorts.
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
Completed
NeuroVive Pharmaceutical AB
Phase 1
This will be a double blind, randomised, placebo controlled, single and multiple oral dose
study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy
volunteers only and will be completed before Part C including patients with primary
mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will
be 25 mg. The dose level in the additional cohorts will be decided following review of data
of the previous cohorts.
Drug-drug Interaction Study of KL1333 in Healthy Subjects
Completed
Abliva AB
Phase 1
A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate
the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and
CYP3A4 in Healthy Subjects
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
